Over the past 12 months, $CTMX has been discussed by 2 distinct FinTwit voices, accumulating 12 mentions between July 2025 and March 2026. Jacob Plieth (@jacobplieth) accounts for 11 of these mentions, establishing himself as the dominant voice discussing CytomX Therapeutics, while Adam Feuerstein (@adamfeuerstein) contributed 1 mention. The biotech category represents the primary focus area for discussion of this ticker.

The most recent activity occurred in mid-March 2026, with @jacobplieth noting that efficacy data for $CTMX showed some decline while suggesting that varseta-M maintained a favorable outlook, with shares trading up 64% at that time. His commentary reflected expectations that efficacy rates would not remain near previously observed levels, indicating evolving clinical perspectives on the company's therapeutic pipeline.